This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Prescribing Information for NGENLA▼(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.
The prevalence of paediatric growth hormone (GH) deficiency is estimated to be between 1 in 3500 and 1 in 4000 children. However, in about 50% of children the cause of growth hormone deficiency (GHD) is unknown (idiopathic growth hormone deficiency).
GHD in children may result from primary pituitary or hypothalamic disorders. Possible causes include:
When there is evidence of short stature (>2 SD below matched population mean), patients should be examined and history checked for factors that may indicate that GHD could be present:
References
Learn more about once-weekly NGENLA, licensed for the treatment of paediatric growth hormone deficiency in patients from 3 years of age
Genotropin (somatropin)
Learn more about Genotropin, a once-daily growth hormone treatment indicated for the treatment of growth hormone deficiency in children
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024